DekaBank Deutsche Girozentrale Cuts Stake in Indivior PLC (NASDAQ:INDV)

DekaBank Deutsche Girozentrale reduced its position in shares of Indivior PLC (NASDAQ:INDV - Free Report) by 62.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,766 shares of the company's stock after selling 76,000 shares during the period. DekaBank Deutsche Girozentrale's holdings in Indivior were worth $692,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of INDV. Scopia Capital Management LP purchased a new stake in Indivior in the third quarter valued at $191,743,000. Vanguard Group Inc. lifted its position in Indivior by 1.6% in the third quarter. Vanguard Group Inc. now owns 5,846,354 shares of the company's stock valued at $134,875,000 after acquiring an additional 90,673 shares during the last quarter. FMR LLC lifted its position in Indivior by 53.5% in the third quarter. FMR LLC now owns 5,498,087 shares of the company's stock valued at $119,339,000 after acquiring an additional 1,915,980 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in Indivior in the second quarter valued at $83,678,000. Finally, Liontrust Investment Partners LLP purchased a new stake in Indivior in the third quarter valued at $43,340,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Stock Down 1.8 %

Shares of INDV traded down $0.35 on Tuesday, hitting $19.39. 115,123 shares of the stock traded hands, compared to its average volume of 121,081. Indivior PLC has a 1 year low of $14.38 and a 1 year high of $26.50. The stock's 50 day moving average is $20.38 and its two-hundred day moving average is $18.41. The firm has a market capitalization of $2.67 billion, a P/E ratio of -969.02 and a beta of 0.46.

Indivior (NASDAQ:INDV - Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.15. Indivior had a net margin of 0.18% and a return on equity of 538.18%. The business had revenue of $293.00 million during the quarter, compared to analyst estimates of $260.00 million. Research analysts forecast that Indivior PLC will post 2.03 EPS for the current year.

Analyst Ratings Changes

Separately, Craig Hallum assumed coverage on shares of Indivior in a research note on Wednesday, April 3rd. They issued a "buy" rating and a $37.00 price objective on the stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.